3Mett H, Rosta S, Schacher B, et al. Outer menmanepermeability and B - lactamase content in Pseudomonasmaltophia clinical isolates and laboratory mutants [ J ]. Rev Infect Dis, 1988,10 (4) :765 - 769.
4Dufersne J, Vezina G, Levsque RC. Cloning and expression of the imipenem hydralysing Blactamase operon forPseudomonas maltophilia in Escherichia coli [ J ]. Antimicrob Agents Chemother, 1998,16 ( 32 ) : 819.
5Morrison AJ,Sader HS,Beach ML.Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital[J].J Clin Microbiol,1986,24(1):52-55.
6Gülmez D,Hascelik G.Stenotrophomonas maltophlia:antimiceobial resistance and molecular typing of an emerging pathogen in a Turkish university hospital[J].Clin Microbiol Infect,2005,11 (11):880-886.
7Mett H,Rosta S,Schacher B,et al.Outer memnane permeability and β-lactamase content in Pseudomonasmaltophia clinical isolates and laboratory mutants[J].Rev Infect Dis,1988,10(4):765-769.
8Dufersne J,Vezina G,Levsque RC.Cloning and expression of the imipenem hydralysingβ-lactamase operon-for Pseudomonas maltophilia in Escherichia coli[J].Antimicrob Agents Chemother,1998,16 (32):819.
9Julve R,Rovira E,Belda A,et al.Clinical manifesrarions of Stenotrophomonas (Xanthomonas) maltophilia infections[J].Ann Med Intern,1998,15(15):476-481.
10Metan G,Uzun O.Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia[J].Antimicrob Agents Chemother,2005,49 (9):3980-3981.
